Gracell Biotechnologies develops CAR-T cell therapies using its FasTCAR platform for next-day manufacturing of younger, less exhausted CAR-T cells, and its TruUCART platform for off-the-shelf allogeneic therapies. The company aims to provide effective treatment options for patients with cancer and autoimmune diseases, addressing the limitations of conventional CAR-T therapies.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional CAR-T cell therapies face limitations in manufacturing speed, cell exhaustion, and accessibility, hindering their effectiveness and availability for patients with cancer and autoimmune diseases. Traditional methods often result in CAR-T cells with reduced activity and increased exhaustion, while allogeneic approaches struggle with immune rejection and limited persistence.
Solution
Gracell Biotechnologies is developing advanced CAR-T cell therapies designed to overcome the limitations of existing treatments. Their FasTCAR platform enables next-day manufacturing of CAR-T cells, resulting in younger, less exhausted cells with potentially enhanced activity. The TruUCART platform focuses on developing off-the-shelf allogeneic CAR-T cell therapies, aiming to increase accessibility for a broader range of patients. Additionally, their SMART CART technology module represents a second-generation enhanced CAR-T molecule designed to address challenges in treating solid tumors.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases who are seeking more effective and accessible CAR-T cell therapy options.
Features
- FasTCAR platform for rapid, next-day manufacturing of CAR-T cells
- TruUCART platform for off-the-shelf allogeneic CAR-T cell therapies
- SMART CART technology module for enhanced CAR-T molecules targeting solid tumors
- Focus on generating younger, less exhausted CAR-T cells with potentially enhanced activity
- Development of cell therapies for both cancer and autoimmune diseases